AbbVie reported revenue of $44.5 billion for the first nine months of 2025, marking an 8% increase from the same period a year earlier. Operating earnings reached $10.5 billion, reflecting disciplined cost management and pricing strategies following the Humira loss of exclusivity. Management reiterated its guidance for high single-digit annual top-line growth through the end of the decade, driven by a balanced mix of legacy immunology franchise performance and new product ramp-up.

The company’s late-stage pipeline comprises approximately 60 mid- to late-stage programmes out of a total portfolio of 90 active compounds, devices, or indications. AbbVie has consistently reinvested around 20% of revenue into research and development over the past three years, focusing on oncology, neuroscience and immunology. Key Phase III readouts expected in 2026 include next-generation therapies targeting systemic autoimmune diseases and novel neurology assets that could add $2 billion to peak annual sales if approved.

In January 2026, AbbVie announced plans to accelerate its obesity franchise leveraging the weight-loss molecule licensed from Danish biotech Gubra. The licensing deal grants AbbVie global commercialization rights and includes a milestone payment structure that could total $1.1 billion. With obesity treatments expected to exceed $25 billion in annual sales by 2030, AbbVie is investing in manufacturing capacity and partnering with payors on outcomes-based agreements to secure favourable reimbursement terms and rapid market access.